Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Johnson & JohnsonJNJ25.104.205.2511.8920.89%3.56%56.62$154.47$55.55147,629$153.10

Detail of Johnson & Johnson

 
CEO
Mr. Joaquin Duato
Employees
131900
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$369B

Company details

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$87.70B
Cost of goods (CoG)
-$27.14B
Gross profit (GP)
$60.56B
Operating expense (OE)
-$38.04B
Research and development (R&D)
-$16.41B
General and administrative (G&A)
-$21.63B
Operating income (OI)
$22.52B
Other income expense (OIE)
-$5.60B
Pretax income (PI)
$17.63B
Tax (TAX)
-$2.86B
Net income (NI)
$14.68B
Johnson & Johnson
JNJ • XNYS • US
$153.10
+1.99 (1.32%)
Stock vs Industry average
  • Industry average

Dividend yield
2.40%
Trailing annual dividend rate
$4.86
Payout ratio
80.33%
EPS
$6.10
Margin profit
16.74%
52 week low
$144.380005
52 week high
$167.800003
50-day simple moving average
$153.95
200-day simple moving average
$154.47
Percent held by insiders
0.09%
Percent held by institutions
72.58%
Dividend yield
3.10%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
JNJ +1.52%
eps change
JNJ 0.00%